VIMRX Names L. William McIntosh Senior Vice President of Business Development and Finance and Chief Financial Officer.WILMINGTON, Del.--(BW HealthWire)--May 21, 1997--VIMRX Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : VMRX) today announced the appointment of L. William McIntosh This article may contain original research or unverified claims. Please help Wikipedia by adding references. See the for details. This article has been tagged since August 2007. as Senior Vice President of Business Development and Finance, and Chief Financial Officer, effective immediately. McIntosh has extensive pharmaceutical industry experience in business development, marketing and sales, commercial operations, finance and technology licensing through his career with Merck & Co., Inc., Medco Containment Services, Inc., Boehringer Mannheim Pharmaceuticals Corporation and Zynaxis, Inc. In addition, the Company announced that Francis O'Connell, currently Vice President of Finance, has been appointed Vice President and Controller. Mr. O'Connell will also continue as Chief Financial Officer of Innovir Laboratories, a majority owned VIMRX affiliate. "Bill McIntosh's broad and extensive business development experience and excellent track record within the pharmaceutical industry make him a strong strategic addition to the VIMRX management team," said Richard L. Dunning, President and Chief Executive Officer of VIMRX. "Business development and finance are critical components of our strategic business plan to generate revenue and aggressively target pharmaceutical and biotechnology industry alliances and collaborations." Most recently, McIntosh served as an independent consultant to SmithKline Beecham Pharmaceuticals and other pharmaceutical and biotechnology companies where he focused on strategic and business planning, marketing, advertising, sales and business development. From 1993 to 1995, he served as Senior Vice President of Business Development and Commercial Operations for Zynaxis, Inc., where he was responsible for corporate-wide business development and commercial operations for the Therapeutics Division. At Boehringer Mannheim Pharmaceuticals Corporation, where McIntosh served as Vice President of Marketing, Sales and Business Development, he was responsible for directing all commercial and operational aspects of the business including accounting, finance and human resources. McIntosh spent 14 years with Merck & Co., Inc., in a progressive career with management positions including Director of Marketing, Antibiotics & Biologicals; Senior Marketing Director, Antibiotics; Director, Licensing & Acquisitions; Associate Director, Advertising; and Product Manager. He later served as Executive Vice President of Marketing and Vice President of Corporate Development for Medco Containment Services, Inc. Mr. McIntosh earned an M.B.A. and a B.S. in Business Administration from Lehigh University. He is a member of the American Economic Association The American Economic Association, or AEA, is the oldest and most important professional organization in the field of economics. It was established in 1885 by religious and social reformer Richard T. , American Marketing Association The American Marketing Association, one of the largest professional associations for marketers, has 38,000 members worldwide in every area of marketing. For over six decades the AMA has been the leading source for information, knowledge sharing and development in the marketing profession. and the Licensing Executives Society. VIMRX Pharmaceuticals Inc., (NASDAQ: VMRX), a biotechnology company based in Wilmington, Delaware, is comprised of a diverse portfolio of companies, technologies and compounds. Through its majority-owned affiliate, Innovir Laboratories, (NASDAQ: INVR), VIMRX is developing oligozymes which control disease-triggering flaws in individuals' genetic chemistry for potential use as both therapeutic agents and as pharmaceutical research tools to aid in gene function analysis and drug discovery target validation. In addition, three compounds are in development: VIMRxyn(R), a chemically synthesized hypericin hy·per·i·cin n. A drug, produced synthetically or as an extract of Saint John's wort, used as an antidepressant and antiviral agent. hypericin studied for the treatment of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , brain cancer, hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. , and blood sterilization sterilization Any surgical procedure intended to end fertility permanently (see contraception). Such operations remove or interrupt the anatomical pathways through which the cells involved in fertilization travel (see reproductive system). ; VM201, a cardiovascular compound recently acquired from Columbia University, that selectively inhibits Factor IXa to manage blood clotting blood clotting, process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called platelets, or thrombocytes, tend to collect and form plugs in blood vessel openings. ; and, VM301, a wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by dermatological agent. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are the success of the Company's clinical trials and the development of competing therapies and/or technologies by other companies. NOTE TO INVESTORS AND EDITORS: VIMRX's press releases are available on the Internet through www.vimrx.com and through BusinessWire's web site at http://www.businesswire.com. The releases also are available at no charge through BusinessWire's fax-on-demand service at 800-411-8792. CONTACT: VIMRX Pharmaceuticals Inc. Laura A. Mastrangelo, 302/998-1734 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion